These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32282866)

  • 41. An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.
    Qin A; Urbanski RW; Yu L; Ahmed T; Mascarenhas J
    Front Oncol; 2023; 13():1109866. PubMed ID: 36776307
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel treatment strategies for myeloproliferative neoplasms.
    Bose P; Masarova L; Verstovsek S
    Rinsho Ketsueki; 2019; 60(9):1176-1185. PubMed ID: 31597841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.
    Pedersen RK; Andersen M; Knudsen TA; Sajid Z; Gudmand-Hoeyer J; Dam MJB; Skov V; Kjaer L; Ellervik C; Larsen TS; Hansen D; Pallisgaard N; Hasselbalch HC; Ottesen JT
    Cancer Med; 2020 Mar; 9(6):2039-2051. PubMed ID: 31991066
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities.
    Liu WD; Hou HA; Li KJ; Qin A; Tsai CY; Sheng WH
    Adv Ther; 2024 Feb; 41(2):847-856. PubMed ID: 38010606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment strategies for low-risk polycythemia vera].
    Ota S
    Rinsho Ketsueki; 2024; 65(8):810-818. PubMed ID: 39231712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b.
    Qin A; Wu D; Liao J; Xie S; Chen H; Gao Y; Cui J; Su X; Miyachi N; Sato T; Li Y; Zhang J; Shen W; Wang W
    Front Pharmacol; 2024; 15():1455979. PubMed ID: 39386026
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron
    Green DS; Nunes AT; David-Ocampo V; Ekwede IB; Houston ND; Highfill SL; Khuu H; Stroncek DF; Steinberg SM; Zoon KC; Annunziata CM
    J Transl Med; 2018 Jul; 16(1):196. PubMed ID: 30012146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel Therapies in Polycythemia Vera.
    Tremblay D; Mascarenhas J
    Curr Hematol Malig Rep; 2020 Apr; 15(2):133-140. PubMed ID: 32034662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.
    Zhang ZR; Duan YC
    Asian Pac J Cancer Prev; 2014; 15(4):1681-4. PubMed ID: 24641389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent polycythemia vera and chronic lymphocytic leukemia: treatment response to pegylated interferon alpha 2a.
    Selinger HA; Ballesteros E; Bona R
    Am J Hematol; 2013 Jun; 88(6):535-6. PubMed ID: 23553722
    [No Abstract]   [Full Text] [Related]  

  • 52. Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.
    Suo SS; Fu RF; Qin A; Shao ZH; Bai J; Chen SN; Duan MH; Zhou H; Xu N; Zhang SJ; Zuo XL; Du X; Wang L; Li P; Zhang XH; Wu DX; Li YN; Zhang JJ; Wang W; Shen WH; Zagrijtschuk O; Sato T; Xiao ZJ; Jin J
    J Hematol; 2024 Apr; 13(1-2):12-22. PubMed ID: 38644985
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.
    Tashi T; Swierczek S; Kim SJ; Salama ME; Song J; Heikal N; King KY; Hickman K; Litton S; Prchal JT
    Leukemia; 2018 Aug; 32(8):1830-1833. PubMed ID: 29556018
    [No Abstract]   [Full Text] [Related]  

  • 54. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
    Verstovsek S; Komatsu N; Gill H; Jin J; Lee SE; Hou HA; Sato T; Qin A; Urbanski R; Shih W; Zagrijtschuk O; Zimmerman C; Mesa RA
    Future Oncol; 2022 Sep; 18(27):2999-3009. PubMed ID: 35924546
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials.
    Gisslinger H
    Turk J Haematol; 2023 Dec; 40(4):266-268. PubMed ID: 38050364
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.
    Sørensen AL; Skov V; Kjær L; Bjørn ME; Eickhardt-Dalbøge CS; Larsen MK; Nielsen CH; Thomsen C; Rahbek Gjerdrum LM; Knudsen TA; Ellervik C; Overgaard UM; Andersen CL; Hasselbalch H
    Blood Adv; 2024 Oct; 8(20):5416-5425. PubMed ID: 39163611
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
    Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
    Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.
    Kiladjian JJ; Cassinat B; Chevret S; Turlure P; Cambier N; Roussel M; Bellucci S; Grandchamp B; Chomienne C; Fenaux P
    Blood; 2008 Oct; 112(8):3065-72. PubMed ID: 18650451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).
    Okikiolu J; Woodley C; Cadman-Davies L; O'Sullivan J; Radia D; Garcia NC; Harrington P; Kordasti S; Asirvatham S; Sriskandarajah P; Saunders J; Saha C; Sanchez I; deLavallade H; McLornan DP; Harrison CN
    Leuk Res Rep; 2023; 19():100360. PubMed ID: 36590864
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.
    Samuelsson J; Hasselbalch H; Bruserud O; Temerinac S; Brandberg Y; Merup M; Linder O; Bjorkholm M; Pahl HL; Birgegard G;
    Cancer; 2006 Jun; 106(11):2397-405. PubMed ID: 16639737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.